Biotech

The Readout Meghana Keshavan

STAT Plus: Novo, Lilly shares sink due to concerns over competition

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Novartis not ready to admit a $3 billion mistake

The Readout Elaine Chen

STAT Plus: The biotech news stories you need to know today

Politics Rachel Cohrs Zhang and John Wilkerson

STAT Plus: Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump

Adam's Take Adam Feuerstein

STAT Plus: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world

Biotech Elaine Chen

STAT Plus: Gilead’s chief medical officer to leave as R&D efforts stall

The Readout Elaine Chen

STAT Plus: It’s happy hour (for now) for Alnylam

Biotech Allison DeAngelis

STAT Plus: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

Biotech Megan Molteni

Vertex sues U.S. government over access to fertility support services for Casgevy patients

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

Biotech Jason Mast

STAT Plus: Early data from Lexeo’s gene therapy for rare heart disease shows promise

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

Adam's Take Adam Feuerstein

STAT Plus: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?

Biotech Elaine Chen

STAT Plus: Novo Nordisk’s weekly insulin rejected by FDA

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

Biotech Allison DeAngelis

STAT Plus: VC Flagship Pioneering raises $3.6 billion in new funds

Biotech Jonathan Wosen

STAT Plus: Biopharma layoffs are leaving the industry’s scientists reeling — and in search of scarce opportunities

Biotech Matthew Herper

STAT Plus: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

Biotech Jason Mast

STAT Plus: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

Biotech Elaine Chen

STAT Plus: Eli Lilly to acquire Morphic for $3.2 billion

Biotech Elaine Chen

STAT Plus: Study links Ozempic to higher risk of eye condition that can cause vision loss

Pharma Adam Feuerstein

STAT Plus: GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data

Biotech Elaine Chen and Matthew Herper

STAT Plus: FDA approves Eli Lilly’s early Alzheimer’s treatment

Biotech John Wilkerson

STAT Plus: Report shows U.S. biotechs are wary of Chinese partnerships due to looming BIOSECURE Act